These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21617185)

  • 1. Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.
    Moon HS; Matarese G; Brennan AM; Chamberland JP; Liu X; Fiorenza CG; Mylvaganam GH; Abanni L; Carbone F; Williams CJ; De Paoli AM; Schneider BE; Mantzoros CS
    Diabetes; 2011 Jun; 60(6):1647-56. PubMed ID: 21617185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and saturable nature of signaling pathways induced by metreleptin in humans: comparative evaluation of in vivo, ex vivo, and in vitro administration.
    Moon HS; Huh JY; Dincer F; Schneider BE; Hasselgren PO; Mantzoros CS
    Diabetes; 2015 Mar; 64(3):828-39. PubMed ID: 25249580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
    Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular leptin signaling following effective weight loss.
    Sahin-Efe A; Polyzos SA; Dincer F; Zaichenko L; McGovern R; Schneider B; Mantzoros CS
    Metabolism; 2015 Aug; 64(8):888-95. PubMed ID: 25998856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
    Ravussin E; Smith SR; Mitchell JA; Shringarpure R; Shan K; Maier H; Koda JE; Weyer C
    Obesity (Silver Spring); 2009 Sep; 17(9):1736-43. PubMed ID: 19521351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin and amylin act in an additive manner to activate overlapping signaling pathways in peripheral tissues: in vitro and ex vivo studies in humans.
    Moon HS; Chamberland JP; Diakopoulos KN; Fiorenza CG; Ziemke F; Schneider B; Mantzoros CS
    Diabetes Care; 2011 Jan; 34(1):132-8. PubMed ID: 20870968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptin administration to overweight and obese subjects for 6 months increases free leptin concentrations but does not alter circulating hormones of the thyroid and IGF axes during weight loss induced by a mild hypocaloric diet.
    Shetty GK; Matarese G; Magkos F; Moon HS; Liu X; Brennan AM; Mylvaganam G; Sykoutri D; Depaoli AM; Mantzoros CS
    Eur J Endocrinol; 2011 Aug; 165(2):249-54. PubMed ID: 21602313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
    J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women.
    Brinkoetter M; Magkos F; Vamvini M; Mantzoros CS
    Am J Physiol Endocrinol Metab; 2011 Jul; 301(1):E99-E104. PubMed ID: 21505147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia.
    Matarese G; La Rocca C; Moon HS; Huh JY; Brinkoetter MT; Chou S; Perna F; Greco D; Kilim HP; Gao C; Arampatzi K; Wang Z; Mantzoros CS
    Proc Natl Acad Sci U S A; 2013 Feb; 110(9):E818-27. PubMed ID: 23382191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early intracellular signaling events induced by in vitro metreleptin administration in cardiac myocytes and uterine smooth muscle cells.
    Choi SK; Park S; Choi Y; Moon HS
    Cell Mol Biol (Noisy-le-grand); 2015 Aug; 61(4):15-20. PubMed ID: 26255263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free leptin index as a marker for leptin action in diabetes and obesity: leptin and soluble leptin receptors relationship with HbA1c.
    Owecki M; Nikisch E; Miczke A; Pupek-Musialik D; Sowiński J
    Neuro Endocrinol Lett; 2010; 31(5):679-83. PubMed ID: 21173748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial.
    Heymsfield SB; Greenberg AS; Fujioka K; Dixon RM; Kushner R; Hunt T; Lubina JA; Patane J; Self B; Hunt P; McCamish M
    JAMA; 1999 Oct; 282(16):1568-75. PubMed ID: 10546697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.
    Sienkiewicz E; Magkos F; Aronis KN; Brinkoetter M; Chamberland JP; Chou S; Arampatzi KM; Gao C; Koniaris A; Mantzoros CS
    Metabolism; 2011 Sep; 60(9):1211-21. PubMed ID: 21741057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin administration in physiological or pharmacological doses does not alter circulating irisin levels in humans.
    Gavrieli A; Panagiotou G; Mantzoros CS
    Int J Obes (Lond); 2016 Sep; 40(9):1461-3. PubMed ID: 27200503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy.
    Kralisch S; Hoffmann A; Estrada-Kunz J; Stumvoll M; Fasshauer M; Tönjes A; Miehle K
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003626
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
    Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Metreleptin Therapy in Patients With Type 1 Diabetes: A Pilot Study.
    Vasandani C; Clark GO; Adams-Huet B; Quittner C; Garg A
    Diabetes Care; 2017 May; 40(5):694-697. PubMed ID: 28223297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Obesity Effect of Chitosan Oligosaccharide Capsules (COSCs) in Obese Rats by Ameliorating Leptin Resistance and Adipogenesis.
    Pan H; Fu C; Huang L; Jiang Y; Deng X; Guo J; Su Z
    Mar Drugs; 2018 Jun; 16(6):. PubMed ID: 29874843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Watanabe H; Miyashita Y; Shirai K
    Metabolism; 2009 May; 58(5):708-13. PubMed ID: 19375596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.